GlaxoSmithKline and Medidata have moved mHealth tools one step closer to the clinical trial mainstream. Having run a pilot project, the partners have concluded that mHealth technologies can deliver reliable, FDA-compliant data and improve the clinical trial experience for patients.
GlaxoSmithKline has long explored a sale of some $3 billion worth of its older drugs, planning to shed products by geographic region to meet buyers' interests. Now, the company could have a more enticing offer on its hands as private equity firm Apollo Global Management is planning to bid GSK's entire portfolio of drugs, rather than snatch up businesses by region, people familiar with the process told Reuters.
Ever since Dendreon's lackluster Provenge launch, the Washington-based biotech's failures have cast a pall over the troubled cancer vaccine field. And the company's bankruptcy won't help with that.
GlaxoSmithKline made a high-profile decision to exit the cancer drug field in its recent deal with Novartis, but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies.
Next-generation hepatitis C drugs may be breaking revenue records now, but eventually a vaccine to prevent the disease could cut into the cash cows' market share. That candidate might come from GlaxoSmithKline, whose hepatitis C vaccine just passed an early test, generating strong and broad immune responses not seen before against the transmissible liver disease.
GlaxoSmithKline is racing to be the first on the market with a new approach to treating severe asthma, filing U.S. and European applications for the injectable mepolizumab as it jockeys with Teva and AstraZeneca.
The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the AstraZeneca, in the latest example of the growing research collaboration between Big Pharma and academia.
A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.
GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover new treatments in the field.
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.